Method Of Using A Transgenic Nonhuman Animal In An In Vivo Test Method (e.g., Drug Efficacy Tests, Etc.) Patents (Class 800/3)
  • GENOMIC EDITING OF GENES INVOLVED IN ALZHEIMER'S DISEASE
    Publication number: 20110023153
    Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with AD. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to study AD development and methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding proteins associated with AD.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 27, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
  • GENOME EDITING OF COGNITION RELATED GENES IN ANIMALS
    Publication number: 20110023152
    Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with cognitive disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences associated with cognitive disorders.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 27, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
  • RABBIT GENOME EDITING WITH ZINC FINGER NUCLEASES
    Publication number: 20110023140
    Abstract: The present invention provides a genetically modified rabbit or cell comprising at least one edited chromosomal sequence. In particular, the chromosomal sequence is edited using a zinc finger nuclease-mediated editing process. The disclosure also provides zinc finger nucleases that target specific chromosomal sequences in the rabbit genome.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 27, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Joseph Bedell, Brian Buntaine, Xiaoxia Cui
  • Susceptibility locus for schizophrenia
    Publication number: 20110016538
    Abstract: Provided are methods for determining the susceptibility of an individual to a neuropsychiatric disorder, or a method of diagnosis or prognosis of the neuropsychiatric disorder (particularly schizophrenia) the methods comprising use of a pericentriolar material 1 (PCM1) marker which is located in the chromosomal region 8p21-22, for example a marker within the PCM1 gene locus or within 1000 kb of it. The invention also provides novel markers, and related materials and methods of detecting them, and identifying further molecules for use in therapy and diagnosis.
    Type: Application
    Filed: March 9, 2010
    Publication date: January 20, 2011
    Inventor: Hugh Malcolm Douglas Gurling
  • GENOME EDITING OF GENES ASSOCIATED WITH TRINUCLEOTIDE REPEAT EXPANSION DISORDERS IN ANIMALS
    Publication number: 20110016540
    Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with trinucleotide repeat expansion disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 20, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
  • CANINE GENOME EDITING WITH ZINC FINGER NUCLEASES
    Publication number: 20110016542
    Abstract: The present invention provides a genetically modified canine or cell comprising at least one edited chromosomal sequence. In particular, the chromosomal sequence is edited using a zinc finger nuclease-mediated editing process. The disclosure also provides zinc finger nucleases that target specific chromosomal sequences in the canine genome.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 20, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Joseph Bedell, Brian Buntaine, Xiaoxia Cui
  • GENOMIC EDITING OF GENES INVOLVED IN INFLAMMATION
    Publication number: 20110016543
    Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding inflammation-related proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding inflammation-related proteins.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 20, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
  • Cellular model of tauopathies for lead identification and drug discovery
    Publication number: 20110016537
    Abstract: The present invention provides polypeptides with modified microtubule binding domains of a tau protein, which polypeptides lead to an increase of neurofibrillary tangles when introduced into a cell. The invention further provides nucleic acid molecules encoding these polypeptides, cells comprising the polypeptides and transgenic animals with cells expressing these polypeptides. The polypeptides of the invention form the basis for animal and cellular models of tau pathology, which form the basis for molecular screens for biomolecules involved in tauopathies, but also for medicaments useful for the treatment of tauopathies.
    Type: Application
    Filed: September 16, 2004
    Publication date: January 20, 2011
    Inventors: Fred S. Wouters, Asparouh I. Iliev
  • GENOME EDITING OF SENSORY-RELATED GENES IN ANIMALS
    Publication number: 20110016541
    Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with nociception or taste disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 20, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
  • GENOME EDITING OF NEUROTRANSMISSION-RELATED GENES IN ANIMALS
    Publication number: 20110016539
    Abstract: The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with neurotransmission disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of using the genetically modified animals or cells disclosed herein to screen agents for toxicity and other effects.
    Type: Application
    Filed: July 23, 2010
    Publication date: January 20, 2011
    Applicant: SIGMA-ALDRICH CO.
    Inventors: Edward Weinstein, Xiaoxia Cui, Phil Simmons
  • KCNN3 AS DIAGNOSTIC AND THERAPEUTIC TARGET FOR NEURODEGENERATIVE DISEASES
    Publication number: 20110010780
    Abstract: The present invention discloses a dysregulation of the KCNN3 gene and the protein products thereof in Alzheimer's disease patients and individuals being at risk of developing Alzheimer's disease. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the KCNN3 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed.
    Type: Application
    Filed: June 2, 2010
    Publication date: January 13, 2011
    Applicant: EVOTEC NeuroSciences GmbH
    Inventors: Johannes Pohlner, Heinz Von Der Kammer
  • COMPOSITIONS AND METHODS FOR OSTEOGENIC GENE THERAPY
    Publication number: 20110004947
    Abstract: The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).
    Type: Application
    Filed: September 10, 2010
    Publication date: January 6, 2011
    Inventors: Kin-Hing William Lau, David J. Baylink, Susan L. Hall, Shin-Tai Chen, Subburaman Mohan
  • Non-human gene-disrupted animal with disrupted Adam11 gene
    Publication number: 20100333216
    Abstract: It is an object of the present invention to provide a non-human gene-disrupted animal with a disrupted ADAM11 gene. According to the present invention, a non-human gene-disrupted animal, wherein either one of or both alleles of an ADAM11 gene are disrupted, is provided.
    Type: Application
    Filed: July 12, 2006
    Publication date: December 30, 2010
    Applicant: EISAI R&D MANAGEMENT CO., LTD
    Inventors: Koji Sagane, Eiki Takahashi, Kazuto Yamazaki, Turo Oki
  • SCREENING METHOD FOR THE COMPOSITION FOR PREVENTION OR TREATMENT OF OSTEOPOROSIS AND METABOLIC BONE DISEASE USING TALLYHO/JNGJ MOUSE
    Publication number: 20100333217
    Abstract: Provided is a method for screening a composition for preventing or treating an osteoporosis and a metabolic bone disease using a TALLYHO/JngJ mouse, and more particularly, to a method for screening a compound effective in preventing and treating a disease caused by abnormalities of a bone metabolism including an osteoporosis, through assessment of a bone regeneration activity, such as acceleration of osteoblast differentiation, inhibition of osteoclast differentiation, variation of cytokine in a serum, as well as a bone mineral density and a bone mineral content in a femur, using a TALLYHO/JngJ mouse instead of a ovariectomized animal generally used in estimating the efficacy of a new osteoporosis medicine in an animal. The screening method has a simple and stable experiment procedure, and can be used in developing an agent for treating an osteoporosis of men and improving the bone mineral content.
    Type: Application
    Filed: April 23, 2008
    Publication date: December 30, 2010
    Applicant: KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Myung Ae Bae, Hyae Gyeong Cheon, Sung Eun Yoo, Hee Youn Kim, Won Hoon Jung, Sang Dal Rhee, Doh Yeon Ahn
  • Gene disruptions, compositions and methods relating thereto
    Patent number: 7858843
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO234, PRO265, PRO309, PRO332, PRO342, PRO356, PRO540, PRO618, PRO944, PRO994, PRO1079, PRO1110, PRO1122, PRO1138, PRO1190, PRO1272, PRO1286, PRO1295, PRO1309, PRO1316, PRO1383, PRO1384, PRO1431, PRO1434, PRO1475, PRO1481, PRO1568, PRO1573, PRO1599, PRO1604, PRO1605, PRO1693, PRO1753, PRO1755, PRO1777, PRO1788, PRO1864, PRO1925, PRO1926, PRO3566, PRO4330, PRO4423, PRO36935, PRO4977, PRO4979, PRO4980, PRO4981, PRO5801, PRO5995, PRO6001, PRO6095, PRO6182, PRO7170, PRO7171, PRO7436, PRO9912, PRO9917, PRO37337, PRO37496, PRO19646, PRO21718, PRO19820, PRO21201, PRO20026, PRO20110, PRO23203 or PRO35250 genes.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: December 28, 2010
    Assignee: Genentech, Inc.
    Inventors: Ling Ling Culbertson, Frederic J. de Sauvage, Charles Montgomery, Zheng-Zheng Shi, Mary Jean Sparks
  • Animal Model Based on Targeted Apoptosis for the Study of Genetic Diseases Such as Parkinson's Disease
    Publication number: 20100325742
    Abstract: Described is the use of a non-human transgenic animal, preferably a mouse, characterized in that it contains a modified version of the gene encoding TIF-IA (a) as an animal model for a disease, (b) for analyzing the function of selected stem cells or (c) for ablating malignant cells or microglia cells. Furthermore, methods for screening a therapeutic compound are described which comprise administering a candidate compound to said non-human transgenic animal (or a cell line derived from said non-human transgenic animal) and monitoring a therapeutic effect of said compound.
    Type: Application
    Filed: March 29, 2007
    Publication date: December 23, 2010
    Inventors: Ingrid Grummt, Rosanna Parlato, Günther Schütz, Xuejun Xuan, Grzegorz Kreiner, Claus Rieker
  • Marks as modifiers of the p53 pathway and methods of use
    Publication number: 20100325743
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Application
    Filed: June 10, 2010
    Publication date: December 23, 2010
    Applicant: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Mario N. Lioubin
  • Methods and kits to detect hereditary angioedema type III
    Publication number: 20100324114
    Abstract: The present invention relates to a method of diagnosing hereditary angioedema type III (HAE III) or a predisposition thereto in a subject being suspected of having developed or of having a predisposition to develop a hereditary angioedema type III or in a subject being suspected of being a carrier for hereditary angioedema type III, the method comprising determining in vitro from a biological sample of said subject the presence or absence of a disease-associated mutation in a nucleic acid molecule regulating the expression of or encoding coagulation factor XII; wherein the presence of such a mutation is indicative of a hereditary angioedema type III or a predisposition thereto.
    Type: Application
    Filed: October 3, 2008
    Publication date: December 23, 2010
    Inventor: Georg Dewald
  • TRANSGENIC NON-HUMAN ANIMALS FOR PHARMACOLOGICAL AND TOXICOLOGICAL STUDIES
    Publication number: 20100319076
    Abstract: The present invention is directed to the production, breeding and use of transgenic non-human animals such as mice in which specific genes or portions of genes have been replaced by homologues from another animal to make the physiology of the animals so modified more like that of the other animal with respect to drug pharmacokinetics and metabolism. The invention also extends to the use of the genetically modified non-human animals of the invention for pharmacological and/or toxicological studies.
    Type: Application
    Filed: August 20, 2010
    Publication date: December 16, 2010
    Applicant: GENE STREAM PTY LIMITED
    Inventor: John Michael Daly
  • STG Promoter And Its Use As A Marker For Taste And Oocyte Cells
    Publication number: 20100319075
    Abstract: The present invention relates to a polynucleotide vector comprising the Simian taste-bud specific gene (STG) promoter operatively linked to a reporter gene. In preferred embodiments, the STG promoter is the murine ortholog of the STG promoter. In other preferred embodiments, the STG promoter is the human ortholog of the STG promoter. In some preferred embodiments, the reporter gene is green fluorescent protein (GFP). Additionally provided are vectors comprising the STG promoter operatively linked to a cre-recombinase gene.
    Type: Application
    Filed: June 11, 2010
    Publication date: December 16, 2010
    Applicant: MONELL CHEMICAL SENSES CENTER
    Inventors: Alexander Alexeyevich Bachmanov, Nataliya Petrovna Bosak, Yutaka Ishiwatari
  • GDE Compositions and Methods
    Publication number: 20100319073
    Abstract: The present invention relates to compositions to treat glycerophosphodiester phosphodiesterase (GDE) related disorders. The invention also relates to methods treating GDE related disorders. The invention further relates to kits for treating GDE related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating GDE related disorders in a subject.
    Type: Application
    Filed: September 29, 2006
    Publication date: December 16, 2010
    Applicant: The Johns Hopkins University
    Inventors: Shanthini Sockanathan, Meenakshi Rao
  • MULTI-TARGETED RNAI THERAPEUTICS FOR SCARLESS WOUND HEALING OF SKIN
    Publication number: 20100319074
    Abstract: The present invention provides small interfering RNA (siRNA) molecules, compositions containing them, and methods of using them for improvement of skin scarless wound healing and other skin conditions, such as psoriasis and lupus-caused cutaneous lesions. The invention includes siRNA molecules and compositions containing them that inhibit the expression of one or more genes that promote pathological or undesired processes in wound healing and methods of using them.
    Type: Application
    Filed: November 6, 2008
    Publication date: December 16, 2010
    Applicant: SIR NAOMICS, INC.
    Inventors: Patrick Y. Lu, Ling Li, Vera Simonenko
  • Methods of screening for agents that modulate the interaction of RGS and G?q and urinary incontinence
    Patent number: 7846671
    Abstract: The present invention provides methods that are useful for the treatment or prevention of smooth muscle disorders such as urinary incontinence and compounds that are useful in such methods.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: December 7, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark Cockett, Chandra S. Ramanathan, Nicholas J. Lodge, Kevin Fitzgerald, Terry Stouch, Lisa Moore, Rachel M. Kindt, Jenny Kopczynski, Stephen Kohl Doberstein
  • Model for neurodegenerative disorders
    Patent number: 7847146
    Abstract: The present invention discloses a double transgenic fly that expresses both Tau protein and the human A?42 peptide of human amyloid-? precursor protein (APP). The double transgenic flies of the present invention display a synergistic altered phenotype as compared to the altered phenotype displayed by transgenic flies expressing either Tau or human A?42 alone, and thus provide for an improved model for neurodegenerative disorders, such as Alzheimer's disease. The invention further discloses methods for identifying for therapeutic compounds to treat neurodegenerative disorders using the double transgenic flies.
    Type: Grant
    Filed: May 25, 2004
    Date of Patent: December 7, 2010
    Assignee: Baylor College of Medicine
    Inventors: Juan Botas, Diego Rincon-Limas, Pedro Fernandez-Funez, Ismael Al-Ramahi
  • METHODS AND APPARATUSES FOR CONDUCTING ASSAYS IN ANIMALS
    Publication number: 20100306861
    Abstract: The invention provides apparatuses, systems, and methods for conducting assays in aquatic animals. The apparatuses, systems, and methods of the invention can be used to identify and/or characterize compounds that modulate morphological, anatomical, or behavioral characteristics. The apparatuses, systems, and methods of the invention can be used to identify and/or characterize compounds that modulate learning or memory.
    Type: Application
    Filed: March 2, 2010
    Publication date: December 2, 2010
    Applicant: The Forsyth Institute
    Inventor: Michael Levin
  • NON-HUMAN ANIMAL MODEL FOR FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN-POSITIVE INCLUSIONS (FTLD-U)
    Publication number: 20100306862
    Abstract: Non-human animal models for frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) are disclosed. The invention relates to a transgenic mouse whose genome comprises a transgene operably linked to a neuronal specific promoter effective for an increased expression of the transgene in the brain of the mouse, in which the transgene comprises a nucleotide sequence encoding TAR DNA-binding protein 43 (TDP-43). The transgenic mouse exhibits reduced or impaired learning and memory capacity, and may further exhibits progressively impaired or reduced motor functions. Methods of using such animal models are also disclosed.
    Type: Application
    Filed: May 24, 2010
    Publication date: December 2, 2010
    Applicant: ACADEMIA SINICA
    Inventors: CHE-KUN JAMES SHEN, KUEN-JER TSAI
  • TREM-2 GENE AND PROTEIN AS INHIBITORS OF EXPRESSION OF GA733-2, AND TRANSGENIC ANIMALS COMPRISING THE SAME AND USES THEREOF
    Publication number: 20100299767
    Abstract: Disclosed are a composition for inhibiting the expression of GA733-2 or for detecting GA733-2, which comprises TREM-2 gene or protein, a transgenic animal containing same, and a method using the same.
    Type: Application
    Filed: February 18, 2009
    Publication date: November 25, 2010
    Applicant: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventors: Hyung-Sik Kang, Eun-Mi Kim, Dong-Hern Kim, Ha-Rim Choi, Eun-Hee Lee, Il-Soo Kim, Chang-Eon Park
  • SEROTONIN 5-HT3A RECEPTORS IN TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
    Publication number: 20100297102
    Abstract: Methods are provided for modulating post-natal migration of neurons. Activation of the 5-HT3A receptor increases migration, while pharmacological blockade of the 5-HT3A receptor disrupts neuroblast migration into the cortex and hippocampus. These neuroblasts mature into GABAergic interneurons, and thus are relevant to conditions associated with disturbances in 5-HT levels and GABAergic inhibition.
    Type: Application
    Filed: June 21, 2007
    Publication date: November 25, 2010
    Inventors: Hannah Monyer, Dragos Inta
  • MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE QPCTL-GENE
    Publication number: 20100299766
    Abstract: A knock-out non-human animal, in particular a mouse, carrying a QPCTL knock-out mutation. Additionally, respective cells and cell lines and methods and compositions for evaluating agents that affect QPCTL, for use in compositions for the treatment of QPCTL-related diseases are disclosed.
    Type: Application
    Filed: May 19, 2010
    Publication date: November 25, 2010
    Applicant: PROBIODRUG AG
    Inventors: Hans-Ulrich Demuth, Anett Stephan, Birgit Koch, Holger Cynis, Stephan Schilling, Reinhard Sedlmeier, Sigrid Graubner
  • Compounds and assays for controlling Wnt activity
    Publication number: 20100298200
    Abstract: The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions.
    Type: Application
    Filed: May 22, 2009
    Publication date: November 25, 2010
    Inventors: Dakai Liu, Xiaofeng Li, Richard Jin, Yuaxin Liang, Wei Cheng, Riddhi Bhattacharyya, Guangrong Zhang
  • MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA
    Publication number: 20100299765
    Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.
    Type: Application
    Filed: May 18, 2010
    Publication date: November 25, 2010
    Inventors: Irina Klimanskaya, Robert Lanza
  • Methods for introducing heterologous cells into fish
    Patent number: 7838726
    Abstract: The invention provides methods of introducing heterologous cells into fish. After introduction cells remain viable, and in some instances proliferate, for sufficient time to conduct a variety of analyses on the heterologous cells or the fish or both. Such methods are useful for screening potential drugs for toxicity toward introduced cells or for capacity to stimulate differentiation and/or proliferation of introduced cells. Such methods are also useful for diagnosing the presence of small quantities of cancerous cells or pathogens in patient tissue samples. Such methods are also useful for culturing cells for subsequent use in cell or tissue engineering.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: November 23, 2010
    Assignee: Phylonix Pharmaceuticals, Inc.
    Inventors: George N Serbedzija, Patricia McGrath
  • Periostin Inhibitory Compositions for Myocardial Regeneration, Methods of Delivery, and Methods of Using Same
    Publication number: 20100291188
    Abstract: We claim the compositions of matter and methods described herein.
    Type: Application
    Filed: December 4, 2009
    Publication date: November 18, 2010
    Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: RUSSELL A. NORRIS, ROBERT G. GOURDIE, MICHAEL P. O'QUINN, ROGER R. MARKWALD
  • Materials and methods relating to protein aggregation in neurodegenerative disease
    Patent number: 7834237
    Abstract: Disclosed is a method of inducing or modeling a disease associated with pathological tau protein aggregation. The method can be carried out in vitro and animal models, and may be used to screen for therapeutic, prognostic or diagnostic agents.
    Type: Grant
    Filed: January 2, 2002
    Date of Patent: November 16, 2010
    Assignee: WisTa Laboratories Ltd.
    Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, David Horsley, Charles Robert Harrington, Franz Theuring, Karsten Stamer, Claudia Zabke
  • Saspase knockout animal
    Patent number: 7834238
    Abstract: Knockout animals in which a gene encoding a SASPase has been deleted (hereinafter, referred to as SASPase KO animals) are provided. The SASPase KO animals deficient in expression of functional SASPase were produced by deleting a gene encoding a stratified epithelium-specific protease, SASPase, through targeted disruption. The SASPase KO animals showed a significant increase in wrinkles on the sides of the body and so on. The SASPase KO animals find utility as animal models of wrinkles.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: November 16, 2010
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Takeshi Matsui, Fumie Kisumi
  • Genetically Modified Rat Models for Cancer
    Publication number: 20100287628
    Abstract: This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
    Type: Application
    Filed: April 23, 2010
    Publication date: November 11, 2010
    Inventors: Eric M. Ostertag, John Stuart Crawford
  • VEGF VARIANTS
    Publication number: 20100287625
    Abstract: This invention relates to a Vascular Endothelial Growth Factor (VEGF) polypeptide, which polypeptide lacks an amino acid sequence encoded by exon 5 of the VEGF gene. This variant of VEGF is capable of eliciting activities associated with VEGF whilst showing resistance to proteolytic degradation. The invention provides uses of this protein and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.
    Type: Application
    Filed: January 18, 2007
    Publication date: November 11, 2010
    Applicant: UNIVERSITE DE LIEGE
    Inventors: Alain Colige, Pierre Mineur, Charles Lambert
  • METHOD OF SCREENING PTP ZETA ACTIVITY PROMOTER OR INHIBITOR
    Publication number: 20100287626
    Abstract: An object of the present invention is to provide a remedy for dysfunction of central monoamine pathway, a method for screening a PTP? inhibitor or activator, which is useful as a remedy for gastric ulcer caused by Helicobacter pylori or pleiotrophin which is a heparin-binding secretory protein, and a non-human model animal being hyposensitive to a stimulant drug, VacA which is a toxin of Helicobacter pylori, or pleiotrophin by utilizing the physiological function of PTP?. After administering a subject material to PTP? knockout mice and wild-type mice, PTP? activity in the PTP? knockout mice and the wild-type mice is compared and evaluated to screen a PTP? inhibitor or activator.
    Type: Application
    Filed: April 8, 2009
    Publication date: November 11, 2010
    Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Masaharu NODA, Akihiro FUJIKAWA
  • Transgenic Zebrafish Models for Neurodegenerative Diseases
    Publication number: 20100287627
    Abstract: The present invention relates to zebrafish models for neurodegenerative disorders that allow screening of compounds for their ability to protect and/or regenerate neurons in vivo in a whole vertebrate organism. The present invention also provides methods of identifying gene targets for neuroprotective compounds, compounds that regenerate neurons and compounds that promote neurogenesis.
    Type: Application
    Filed: December 23, 2009
    Publication date: November 11, 2010
    Inventor: Amy L. Rubinstein
  • SGRF gene-modified mouse
    Patent number: 7829757
    Abstract: A targeting vector was constructed by replacing exon regions in the SGRF gene with appropriate drug marker genes. This vector was transfected into mouse ES cell lines to obtain chimeric mice, which were then crossed with C57BL/6J mice to obtain mice comprising cells in which one SGRF gene alleles was inactivated. By crossing these mice with each other, the present inventors succeeded in producing mice in which both SGRF gene alleles were inactivated. These genetically modified animals can be used to predict the side effects of drugs such as SGRF antagonists.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: November 9, 2010
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kiyoshi Habu, Yuichi Hirata
  • Selecting animals for desired genotypic or potential phenotypic properties
    Publication number: 20100281547
    Abstract: Described are methods to select animals, such as mammals, particularly domestic animals, breeding animals or animals destined for slaughter, for having desired genotypic or potential phenotypic properties, in particular, related to muscle mass and/or fat deposition lean meat, lean back fat, sow prolificacy and/or sow longevity. Provided is a method for selecting an animal having desired genotypic or potential phenotypic properties comprising testing the animal, a parent of the animal or its progeny for the presence of a nucleic acid modification affecting the activity of an evolutionary conserved CpG island, located in intron 3 of an IGF2 gene and/or for the presence of a nucleic acid modification affecting binding of a nuclear factor to an IGF2 gene.
    Type: Application
    Filed: February 12, 2010
    Publication date: November 4, 2010
    Inventors: Leif Andersson, Goran Andersson, Michel Georges, Nadine Buys
  • Animal models for demyelination disorders
    Publication number: 20100281548
    Abstract: This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an animal model that exhibits hypomyelination. The compositions and methods embodied in the present invention are particularly useful for drug screening and/or treatment of demyelination disorders.
    Type: Application
    Filed: April 28, 2010
    Publication date: November 4, 2010
    Applicant: UNIVERSITY OF CHICAGO
    Inventors: Brian Popko, Wensheng Lin
  • Desmin gene having novel point mutation causative of dilated cardiomyopathy
    Patent number: 7825292
    Abstract: The present invention is intended to elucidate the cause of severe cardiomyopathy in subline (T) not manifesting the macroscopic cardiac hypertrophy, which has been separated from a hamster (B) with hypertrophic cardiomyopathy and clarify the pathogenic cause of dilated cardiomyopathy, thereby establishing a method of detecting and identifying dilated cardiomyopathy and a method of preventing and treating the same. The present invention relates to a desmin gene having a point mutation at the site corresponding to the 571-position of the base sequence in the cDNA translation region of Syrian hamster; a polypeptide thereof; and an oligonucleotide consisting of 5 to 250 bases including the point mutation site or an oligonucleotide having a sequence complementary thereto.
    Type: Grant
    Filed: October 22, 2007
    Date of Patent: November 2, 2010
    Assignee: Japan Science and Technology Agency
    Inventor: Aiji Sakamoto
  • MOUSE MODEL FOR DEPRESSION, SCHIZOPHRENIA AND ALZHEIMER'S DISEASE
    Publication number: 20100275274
    Abstract: The present invention relates to Glycine N-methyltransferase (GNMT) animal model and use thereof.
    Type: Application
    Filed: April 28, 2009
    Publication date: October 28, 2010
    Applicant: NATIONAL YANG-MING UNIVERSITY
    Inventors: YI-MING CHEN, CHING-PING YANG
  • ZEBRAFISH MODEL FOR ASSESSING GASTROINTESTINAL MOTILITY
    Publication number: 20100275276
    Abstract: The present invention has demonstrated the presence of the zebrafish KIT protein resulting from the expression of the kit gene in the zebrafish GI tract. As expression of the KIT protein is correlated with ICC in other species, the expression of the KIT protein in zebrafish indicates the presence of ICC in the zebrafish GI tract. ICC are required for spontaneous, coordinated contractions of GI smooth muscle. The present invention provides a zebrafish-based model system useful for elucidating the cellular and molecular mechanisms of gastrointestinal (GI) function and for identifying molecular targets for treating GI motility disorders in human.
    Type: Application
    Filed: February 16, 2010
    Publication date: October 28, 2010
    Applicant: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
    Inventor: Adam Rich
  • HADHs as Modifiers of the p21 Pathway and Methods of Use
    Publication number: 20100275275
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Application
    Filed: August 5, 2009
    Publication date: October 28, 2010
    Applicant: EXELIXIS INC.
    Inventors: Lori Friedman, Gregory D. Plowman, Roel P. Funke, Marcia Belvin, Danxi Li, Stephanie A. Robertson
  • FcRN ANTIBODIES AND USES THEREOF
    Publication number: 20100266530
    Abstract: In certain embodiments, this present invention provides polypeptide compositions (e.g., antibodies and antigen binding portions thereof that bind to FcRn), and methods for modulating FcRn activity. In other embodiments, the present invention provides methods and compositions for treating autoimmune disorders.
    Type: Application
    Filed: April 14, 2006
    Publication date: October 21, 2010
    Applicant: THE JACKSON LABORATORY
    Inventors: Derry Charles Roopenian, Shreeram Akilesh, Gregory James Christianson, Stefka Petkova, Petko M. Petkov, Thomas J. Sproule, Emanuele Pesavento
  • METHODS, COMPOSITIONS AND TRANSGENIC MODELS RELATED TO THE INTERACTION OF T-CADHERIN AND ADIPONECTIN
    Publication number: 20100269180
    Abstract: Disclosed are methods, compositions and transgenic models related to the interaction of T-cadherin and adiponectin.
    Type: Application
    Filed: April 16, 2010
    Publication date: October 21, 2010
    Inventors: Barbara Ranscht, Martin Denzel
  • Properdin Modulation of Alternative Pathway and Uses Thereof
    Publication number: 20100263061
    Abstract: This invention relates to selective activation of the alternative pathway (AP) using anti-Properdin antibodies. Specifically, the invention relates to methods for treating an AP complement-mediated pathology or AP mediated condition in a subject by contacting the subject with an anti-Properdin antibodies. Likewise, properdin knockout transgenic non-human mammals and their use are provided.
    Type: Application
    Filed: June 11, 2008
    Publication date: October 14, 2010
    Inventor: Wenchao Song
  • ANIMAL MODEL FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CYSTIC FIBROSIS
    Publication number: 20100263064
    Abstract: A nonhuman transgenic mammal is described whose genome comprises a promoter construct operably linked to a heterologous DNA encoding an epithelial sodium channel ? subunit, wherein said promoter construct directs expression of the epithelial sodium channel ? subunit in lung epithelial cells of said animal, and wherein said transgenic mammal has increased lung mucus retention as compared to the corresponding wild-type mammal. The animal is useful in screening compounds for activity in treating lung diseases such as cystic fibrosis and chronic obstructive pulmonary disease.
    Type: Application
    Filed: June 25, 2010
    Publication date: October 14, 2010
    Inventors: Richard C. Boucher, JR., Wanda O'Neal, Barbara Grubb, Marcus Mall